Alto Neuroscience (ANRO) Net Income (2023 - 2026)
Alto Neuroscience (ANRO) posted Net Income of -$26.1 million for Q1 2026, down 71.25% sequentially from -$15.3 million in Q4 2025, and down 64.82% YoY from -$74.2 million in Q1 2025.
Alto Neuroscience (ANRO) Net Income (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Net Income for 4 years, with the latest figure at -$26.1 million in Q1 2026.
- Quarterly Net Income fell 64.82% year-over-year to -$26.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.3 billion (down 3479.2% YoY) and the FY2025 annual result came in at -$111.9 million, down 15.18% from the prior year.
- Net Income slipped to -$26.1 million in Q1 2026 per ANRO's latest filing, from -$15.3 million in the prior quarter.
- Over five years, Net Income peaked at -$7.3 million in Q1 2023 and troughed at -$1.9 billion in Q3 2025.
- A 4-year average of -$183.6 million and a median of -$15.3 million in 2025 frame the typical range for Net Income.
- The widest YoY moves for Net Income: up 2.64% in 2025, down 10975.11% in 2025.
- Over 4 years, Net Income stood at -$10.9 million in 2023, then plunged by 36.03% to -$14.9 million in 2024, then retreated by 2.64% to -$15.3 million in 2025, then tumbled by 71.25% to -$26.1 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$26.1 million, -$15.3 million, and -$1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | -157.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -157.26 Mn |
| Mar 31, 2026 | -26.12 Mn |
| Dec 31, 2025 | -15.25 Mn |
| Sep 30, 2025 | -1.85 Bn |
| Jun 30, 2025 | -379.00 Mn |
| Mar 31, 2025 | -15.85 Mn |
| Dec 31, 2024 | -14.86 Mn |
| Sep 30, 2024 | -16.74 Mn |
| Jun 30, 2024 | -16.08 Mn |
| Mar 31, 2024 | -13.17 Mn |
| Dec 31, 2023 | -10.93 Mn |
| Sep 30, 2023 | -9.40 Mn |
| Jun 30, 2023 | -8.86 Mn |
| Mar 31, 2023 | -7.30 Mn |